Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
E-pub ahead of print

Recovery of Cardiac Function Following COVID-19 - ECHOVID-19: A Prospective Longitudinal Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Mega-trials in heart failure: effects of dilution in examination of new therapies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: The degree of cardiovascular sequelae following COVID-19 remains unknown. The aim of this study was to investigate whether cardiac function recovers following COVID-19.

METHODS AND RESULTS: A consecutive sample of patients hospitalized with COVID-19 were prospectively included in this longitudinal study. All patients underwent an echocardiographic examination during hospitalization and two months later. All participants were successfully matched 1:1 with COVID-19-free controls on age and sex. A total of 91 patients were included in this study (mean age 63±12 and 59% males). A median of 77 [72,92] days passed between the two examinations. Right ventricular (RV) function improved following resolution of COVID-19: tricuspid annular plane systolic excursion (TAPSE): (2.28cm±0.40 vs 2.11cm±0.38, P<0.001) and longitudinal strain of the right ventricle (RVLS) (25.3%±5.5 vs 19.9%±5.8, P<0001). In contrast, left ventricular (LV) systolic function assessed by global longitudinal strain (GLS) did not significantly improve (17.4±2.9 vs 17.6%±3.3, P=0.6). NT-proBNP decreased between the two examinations (177.6 (80.3,408,0) vs 1.7 (5.7,24.0), P<0.001). None of the participants had elevated troponins at follow-up compared to 18 (27.7%) during hospitalization. Recovered COVID-19 patients had significantly lower GLS (17.4%±2.9 vs 18.8%±2.9, P=0.001 & adjusted P=0.004), TAPSE (2.28cm±0.40 vs 2.67cm±0.44, P<0.001 & adjusted P<0.001), and RVLS (25.3%±5.5 vs 26.6%±5.8, P=0.50 & adjusted P<0.001) compared to matched controls.

CONCLUSION: Acute COVID-19 affected negatively RV function and cardiac biomarkers but recovered following resolution of COVID-19. In contrast, the observed reduced LV function during acute COVID-19 did not improve post-COVID-19. Compared to the matched controls, both LV and RV function remained impaired.

TidsskriftEuropean Journal of Heart Failure
StatusE-pub ahead of print - 12 sep. 2021

ID: 67612004